NCT04335604View on ClinicalTrials.gov

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions
Advanced Solid Tumors
Interventions
DRUG

JPI-547

The dose levels will be escalated following a 3+3 dose escalation scheme.

Trial Locations (2)

13620

Seoul National University Bundang Hospital, Seongnam-si

03080

Seoul National University College of Medicine, Seoul

Sponsors
All Listed Sponsors
collaborator

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

lead

Onconic Therapeutics Inc.

INDUSTRY

NCT04335604 - A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter